230 related articles for article (PubMed ID: 26765406)
21. The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.
Terada N; Kamoto T; Tsukino H; Mukai S; Akamatsu S; Inoue T; Ogawa O; Narita S; Habuchi T; Yamashita S; Mitsuzuka K; Arai Y; Kandori S; Kojima T; Nishiyama H; Kawamura Y; Shimizu Y; Terachi T; Sugi M; Kinoshita H; Matsuda T; Yamada Y; Yamamoto S; Hirama H; Sugimoto M; Kakehi Y; Sakurai T; Tsuchiya N
BMC Cancer; 2019 Feb; 19(1):156. PubMed ID: 30770773
[TBL] [Abstract][Full Text] [Related]
22. Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.
Kearns B; Lloyd Jones M; Stevenson M; Littlewood C
Pharmacoeconomics; 2013 Jun; 31(6):479-88. PubMed ID: 23580356
[TBL] [Abstract][Full Text] [Related]
23. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
24. Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Pobel C; Auclin E; Teyssonneau D; Laguerre B; Cancel M; Boughalem E; Noel J; Brachet PE; Maillet D; Barthelemy P; Helissey C; Thibault C; Oudard S
Cancer Med; 2021 Sep; 10(18):6304-6309. PubMed ID: 34382352
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.
Kosaka T; Shinojima T; Morita S; Oya M
Cancer Sci; 2018 May; 109(5):1570-1575. PubMed ID: 29493842
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
Clément-Zhao A; Auvray M; Aboudagga H; Blanc-Durand F; Angelergues A; Vano YA; Mercier F; El Awadly N; Verret B; Thibault C; Oudard S
BJU Int; 2018 Feb; 121(2):203-208. PubMed ID: 28370882
[TBL] [Abstract][Full Text] [Related]
28. The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Belderbos BPS; de With M; Singh RK; Agema BC; El Bouazzaoui S; Oomen-de Hoop E; de Wit R; van Schaik RHN; Mathijssen RHJ; Bins S
Cancer Chemother Pharmacol; 2020 Mar; 85(3):547-553. PubMed ID: 31893292
[TBL] [Abstract][Full Text] [Related]
29. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program.
Castellano D; Antón Aparicio LM; Esteban E; Sánchez-Hernández A; Germà JR; Batista N; Maroto P; Pérez-Valderrama B; Luque R; Méndez-Vidal MJ;
Expert Opin Drug Saf; 2014 Sep; 13(9):1165-73. PubMed ID: 25001524
[TBL] [Abstract][Full Text] [Related]
30. [Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: the TROPIC study in France].
Pouessel D; Oudard S; Gravis G; Priou F; Shen L; Culine S
Bull Cancer; 2012; 99(7-8):731-41. PubMed ID: 22743148
[TBL] [Abstract][Full Text] [Related]
31. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
32. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: results of a compassionate use program in the Netherlands.
Wissing MD; van Oort IM; Gerritsen WR; van den Eertwegh AJ; Coenen JL; Bergman AM; Gelderblom H
Clin Genitourin Cancer; 2013 Sep; 11(3):238-250.e1. PubMed ID: 23659772
[TBL] [Abstract][Full Text] [Related]
33. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab).
Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullén A
Eur J Cancer; 2018 Jul; 97():33-40. PubMed ID: 29685343
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).
Süner A; Aydın D; Hacıoğlu MB; Doğu GG; İmamoğlu GI; Menekşe S; Pilancı KN; Yazıcı ÖK; Koca D; Karaağaç M; Akyol M; Akman T; Ergen S; Avcı N; Kaçan T; Bozkurt O; Kefeli U; Urakçı Z; Araz M; Arpacı E; Harputlu H; Sevinç A
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(7):1238-43. PubMed ID: 27097941
[TBL] [Abstract][Full Text] [Related]
35. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study.
Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
Med Oncol; 2019 Feb; 36(4):32. PubMed ID: 30815799
[TBL] [Abstract][Full Text] [Related]
37. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Armstrong AJ; Humeniuk MS; Healy P; Szmulewitz R; Winters C; Kephart J; Harrison MR; Martinez E; Mundy K; Halabi S; George D
Prostate; 2017 Mar; 77(4):385-395. PubMed ID: 27862097
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Omlin A; Sartor O; Rothermundt C; Cathomas R; De Bono JS; Shen L; Su Z; Gillessen S
Clin Genitourin Cancer; 2015 Aug; 13(4):e205-e208. PubMed ID: 25733056
[TBL] [Abstract][Full Text] [Related]
39. [Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Heck MM; Höppner M; Horn T; Thalgott M; Gschwend JE; Retz M
Urologe A; 2012 Mar; 51(3):390-7. PubMed ID: 22331349
[TBL] [Abstract][Full Text] [Related]
40. [Docetaxel-Cabazitaxel-Enzalutamide Versus Docetaxel-Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer].
Richter I; Dvořák J; Bartoš J
Klin Onkol; 2017; 30(4):289-293. PubMed ID: 28832175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]